Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
全站搜尋
:::

劉峻宇 (Chun-Yu Liu)

劉峻宇(Chun-Yu Liu)圖 掛號

[簡介]

  • 學歷
    • 國立陽明大學 生物藥學研究所 博士
    • 台北醫學大學 醫學系 醫學士
  • 經歷
    現職：
    • 2018- 迄今 臺北榮民總醫院輸血醫學科 科主任
    • - 迄今 國立陽明交通大學 醫學系 內科學科 副教授
    經歷：
    • - 臺北榮民總醫院 腫瘤醫學部 藥物治療科 主治醫師
    • - 臺北榮民總醫院 內科部 血液腫瘤科 住院醫師、總醫師
  • 醫療專長
    1. 腫瘤內科學、血液學、抗癌新藥機轉、周邊血液幹細胞及骨髓移植、乳癌、淋巴癌、血液癌症、胸腺癌/胸腺腫瘤
  • 證照
    內科專科醫師、腫瘤內科專科醫師、癌症安寧緩和醫療專科醫師、血液病科專科醫師、血液及骨髓移植專科醫師

[著作]

PubMed

  1. Liu CY, Huang TT, Huang CT, Hu MH, Wang DS, Wang WL, Tsai WC, Lee CH, Lau KY, Yang HP, Chen MH, Shiau CW, Tseng LM*, Chen KF*.  EGFR-Independent Elk1/CIP2A Signalling Mediates Apoptotic Effect of An Erlotinib Derivative TD52 in Triple-Negative Breast Cancer Cells. Eur J Cancer 2017 Feb; 72(): 112-23. Epub 2016 Dec. (IF: 6.029; Oncology 34/217)

  2. Liu CY, Hsieh FS, Chu PY, Tsai WC, Huang CT, Yu YB, Huang TT, Ko PS, Hung MH, Wang WL, Shiau CW, Chen KF*.  Carfilzomib Induces Leukaemia Cell Apoptosis via Inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and Activating PP2A Not Related to Proteasome Inhibition. Br J Haematol 2017 Jun; 177(5): 726-40. Epub 2017 Mar. (IF: 5.670; Hematology 10/70)

  3. Liu CY, Su JC, Huang TT, Chu PY, Huang CT, Wang WL, Lee CH, Lau KY, Tsai WC, Yang HP, Shiau CW, Tseng LM*, Chen KF*.  Sorafenib Analogue SC-60 Induces Apoptosis through the SHP-1/STAT3 Pathway and Enhances Docetaxel Cytotoxicity in Triple-Negative Breast Cancer Cells. Mol Oncol 2017 Mar; 11(3): 266-79. Epub 2017 Feb. (IF: 5.314; Oncology 40/217)

  4. Liu CY, Hsu CC, Huang TT, Lee CH, Chen JL, Yang SH, Jiang JK, Chen WS, Lee KD, Teng HW*.  ER Stress-Related ATF6 Upregulates CIP2A and Contributes to Poor Prognosis of Colon Cancer. Mol Oncol 2018 Jul. [Epub ahead of print] (IF: 5.264; Oncology 46/222)

  5. Su JC, Mar AC, Wu SH, Tai WT, Chu PY, Wu CY, Tseng LM, Lee TC, Chen KF, Liu CY*, Chiu HC*, Shiau CW*.  Disrupting VEGF-A Paracrine and Autocrine Loops By Targeting SHP-1 Suppresses Triple Negative Breast Cancer Metastasis. Sci Rep 2016 Jul; 6(): 28888. (IF: 5.228; Multidisciplinary Sciences 7/63)

  6. Hu MH, Chen LJ, Chen YL, Tsai MS, Shiau CW, Chao TI, Liu CY*, Kao JH*, Chen KF*.  Targeting SHP-1-STAT3 signaling: A Promising Therapeutic Approach for the Treatment of Cholangiocarcinoma. Oncotarget 2017 Sep; 8(39): 65077-89. Epub 2017 May. (IF: 5.168; Oncology 44/217; Cell Biology 48/189)

  7. Liu CY, Huang TT, Chu PY, Huang CT, Lee CH, Wang WL, Lau KY, Tsai WC, Chao TI, Su JC, Chen MH, Shiau CW, Tseng LM*, Chen KF*.  The Tyrosine Kinase Inhibitor Nintedanib Activates SHP-1 and Induces Apoptosis in Triple-Negative Breast Cancer Cells. Exp Mol Med 2017 Aug; 49(8): e366. (IF: 5.063; Medicine, Research & Experimental 13/128; Biochemistry & Molecular Biology 48/286)

  8. Liu CY, Hu MH, Hsu CJ, Huang CT, Wang DS, Tsai WC, Chen YT, Lee CH, Chu PY, Hsu CC, Chen MH, Shiau CW, Tseng LM*, Chen KF*.  Lapatinib Inhibits CIP2A/PP2A/p-Akt Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells. Oncotarget 2016 Feb; 7(8): 9135-49. (IF: 5.008; Oncology 36/213; Cell Biology 43/187)

  9. Liu CY, Chen KF, Chao TI, Chu PY, Huang CT, Huang TT, Yang HP, Wang WL, Lee CH, Lau KY, Tsai WC, Su JC, Wu CY, Chen MH, Shiau CW, Tseng LM*.  Sequential Combination of Docetaxel with a SHP-1 Agonist Enhanced Suppression of p-STAT3 Signaling and Apoptosis in Triple Negative Breast Cancer Cells. J Mol Med (Berl) 2017 Sep; 95(9): 965-75. Epub 2017 Jun. (IF: 4.686; Medicine, Research & Experimental 18/128; Genetics & Heredity 27/167)

  10. Liu CY, Wu CY, Petrossian K, Huang TT, Tseng LM, Chen S*.  Treatment for the Endocrine Resistant Breast Cancer: Current Options and Future Perspectives. J Steroid Biochem Mol Biol 2017 Sep; 172(): 166-75. Epub 2017 Jul. (IF: 4.561; Endocrinology & Metabolism 27/138; Biochemistry & Molecular Biology 60/286)

  11. Hu MH, Huang TT, Chao TI, Chen LJ, Chen YL, Tsai MH, Liu CY*, Kao JH*, Chen KF*.  Serine/Threonine Protein Phosphatase 5 is a Potential Therapeutic Target in Cholangiocarcinoma. Liver Int 2018 May. [Epub ahead of print] (IF: 4.500; Gastroenterology & Hepatology 16/80)

  12. Huang TT, Su JC, Liu CY*, Shiau CW*, Chen KF*.  Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. Int J Mol Sci 2017 Jun; 18(6): E1234. (IF: 3.226; Chemistry, Multidisciplinary 54/166; Biochemistry & Molecular Biology 116/286)

  13. Hung MH, Liu CJ, Teng CJ, Hu YW, Yeh CM, Chen SC, Chien SH, Hung YP, Shen CC, Chen TJ, Tzeng CH, Liu CY*.  Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study. PLoS One 2016 Feb; 11(2): e0148597. (IF: 3.057; Multidisciplinary Sciences 11/63)

  14. Chen CT, Liu CY, Yu YB, Liu CJ, Hsiao LT, Gau JP, Chiou TJ, Liu JH, Liu YC*.  Characteristics and Risk of Chronic Graft-Versus-Host Disease of Liver in Allogeneic Hematopoietic Stem Cell Transplant Recipients. PLoS One 2017 Sep; 12(9): e0185210. (IF: 2.806; Multidisciplinary Sciences 15/64)

  15. Liu CY, Lau KY, Hsu CC, Chen JL, Lee CH, Huang TT, Chen YT, Huang CT, Lin PH, Tseng LM*.  Combination of palbociclib with Enzalutamide Shows in Vitro Activity in RB Proficient and Androgen Receptor Positive Triple Negative Breast Cancer Cells. PLoS One 2017 Dec; 12(12): e0189007. (IF: 2.806; Multidisciplinary Sciences 15/64)

  16. Ko PS, Yu YB, Liu YC, Wu YT, Hung MH, Gau JP, Liu CJ, Hsiao LT, Chen PM, Chiou TJ, Liu CY*, Liu JH.  Moderate Anemia at Diagnosis is an Independent Prognostic Marker of the EUTOS, Sokal and Hasford Scores for Survival and Treatment Response in Chronic-Phase, Chronic Myeloid Leukemia Patients with Frontline Imatinib. Curr Med Res Opin 2017 Oct; 33(10): 1737-44. Epub 2017 Aug. (IF: 2.757; Medicine, General & Internal 33/154; Medicine, Research & Experimental 53/128)

  17. Chen JL, Chu PY, Huang CT, Huang TT, Wang WL, Lee YH, Chang YY, Dai MS, Shiau CW, Liu CY*. Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma. Mol Med 2022;28(1):93. (IF:6.382)
  18. Cheng HF, Tsai YF*, Huang CC, Lien PJ, Wang YL, Hsu CY, Chen YJ, Liu CY, Chao TC, Lin YS, Feng CJ, Chiu JH, Chau GY, Tseng LM*. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital. J Chin Med Assoc 2022;85(1):88-94. (IF:3.396)
  19. Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou XF, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, Wu SJ*. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. J Hematol Oncol 2022;15(1):56. (IF:23.168)
  20. Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM*. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Ann Surg Oncol 2022;29(6):3578-3590. (IF:4.339)
  21. 2,5Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM*. ASO Visual Abstract: Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Ann Surg Oncol 2022;29(Suppl 3):618-619. (IF:4.339)
  22. Huang CP, Tsai YF, Lin YS, Liu CY, Huang TT, Huang CC, Chiu JH*, Tseng LM. Overexpression of multiple epidermal growth factor like domains 11 rescues anoikis survival through tumor cells-platelet interaction in triple negative breast Cancer cells. Life Sci 2022;299:125041. (IF:6.780)
  23. Lai JI, Chao TC, Liu CY, Huang CC, Tseng LM*. A systemic review of taxanes and their side effects in metastatic breast cancer. Front Oncol 2022;12:940239. (IF:5.738)
  24. Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI*. CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER plus breast cancer. Clin Transl Oncol 2022;24(11):2120-2135. (IF:3.340)
  25. Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI*. CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer (Aug, 10.1007/s12094-022-02881-0, 2022). Clin Transl Oncol 2022;24(11):2251-2253. (IF:3.340)
  26. Lin CY, Yu CJ, Shen CI, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI*. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. Med Oncol 2022;39(12):242. (IF:3.738)
  27. Sun RL, Pan SW*, Feng JY, Liu CY, Chen YM. Osteoblastic flare phenomenon in a patient treated for disseminated non-tuberculous mycobacterial infection. Thorax 2022;77(11):1152-1153. (IF:9.203)

 

回到最上